MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 30516-87-1
MCE 国际站:Zidovudine
产品活性:Zidovudine 是一种核苷逆转录酶抑制剂 (NRTI),有潜力用于 HIV 感染的研究。Zidovudine 增强 CRISPR/Cas9调节的编辑频率。
研究领域:Anti-infection | Cell Cycle/DNA Damage
作用靶点:HIV | CRISPR/Cas9
In Vitro: Zidovudine inhibits SVG, Primary human fetal astrocytes (PFA), peripheral blood mononuclear cells (PBMC), and monocyte-derived macrophages (MDM) with EC50 of 17, 1311, 8, and 5 nM, respectively. Zidovudine inhibits SVG, PFA, PBMC, and MDM with EC90 of 0.205 μM, 44.157 μM, 0.481 μM, and 0.219 μM, respectively. Genome editing via CRISPR/Cas9 has become an efficient and reliable way to make precise, targeted changes to the genome of living cells. CXCR4 is a co-receptor for the human immunodeficiency virus type 1 (HIV-1) infection and has been considered as an important therapeutic target for AIDS. CXCR4 mediates viral entry into human CD4+ cells by binding to envelope protein, gp120. Human CXCR4 gene is efficiently disrupted by CRISPR/Cas9-mediated genome editing, leading to HIV-1 resistance of human primary CD4+ T cells. The Cas9-mediated ablation of CXCR4 demonstrated high specificity and negligible off-target effects without affecting cell division and propagation.
In Vivo: Intravitrous injection of the NRTIs Lamivudine (3TC), Zidovudine (AZT), or Abacavir (ABC) suppresses the laser-induced choroidal neovascularization (CNV) in wild-type mice compared to PBS vehicle. The mean level of VEGF-A in the RPE/choroid, which peaks on day 3 after laser injury, is significantly reduced in 3TC-, AZT- and ABC-treated eyes compared with control eyes in wild-type mice, but not inP2rx7-/- mice.
相关产品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Cell Cycle/DNA Damage Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | CNS-Penetrant Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Nucleotide Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Tumorigenesis-Related Compound Library | Rare Diseases Drug Library | Children’s Drug Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Non-steroidal Anti-Inflammatory Compound Library | Off-patent Drug Library | Mitochondrial Toxicity Compound Library | Peldesine dihydrochloride | Abacavir sulfate | HIV-IN-6 | Epicoccone B | Ditiocarb | Nevirapine | DAPTA | Aloperine | Elipovimab | HIV-1 inhibitor-52 | PMEDAP | Integracin B | FNC-TP | DDX3-IN-1 | Sennoside A | CK-666 | HIV-1 inhibitor-44 | Flavopiridol | Claficapavir | Atazanavir | 1-Deoxymannojirimycin hydrochloride | TC14012 | (Z)-9-Propenyladenine | Apabetalone | CCR5 antagonist 2 | 2F5 epitope | HIV-1 inhibitor-23 | Apelin-36(rat, mouse) | MIV-150 | Tenofovir alafenamide hemifumarate
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。